Elanco Animal Health (NYSE:ELAN) Given Buy Rating at Stifel Nicolaus

Stifel Nicolaus reiterated their buy rating on shares of Elanco Animal Health (NYSE:ELAN) in a research report released on Thursday, Benzinga reports. Stifel Nicolaus currently has a $20.00 price objective on the stock.

ELAN has been the subject of several other reports. Piper Sandler dropped their price objective on shares of Elanco Animal Health from $19.00 to $16.00 and set a neutral rating for the company in a research note on Monday, July 1st. Barclays cut their price target on shares of Elanco Animal Health from $23.00 to $21.00 and set an overweight rating on the stock in a report on Friday, June 28th. Finally, Morgan Stanley lowered shares of Elanco Animal Health from an overweight rating to an equal weight rating and reduced their price objective for the stock from $17.00 to $15.00 in a research report on Thursday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has an average rating of Hold and an average target price of $17.29.

Elanco Animal Health Stock Performance

Elanco Animal Health stock opened at $15.07 on Thursday. The company has a quick ratio of 1.75, a current ratio of 2.93 and a debt-to-equity ratio of 0.92. Elanco Animal Health has a twelve month low of $8.52 and a twelve month high of $18.80. The company’s 50-day moving average price is $13.92 and its 200-day moving average price is $15.17. The company has a market cap of $7.44 billion, a PE ratio of -5.68, a price-to-earnings-growth ratio of 1.44 and a beta of 1.40.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.06. The company had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.18 earnings per share. On average, equities research analysts forecast that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons bought 100,000 shares of Elanco Animal Health stock in a transaction dated Monday, August 12th. The shares were acquired at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the transaction, the chief executive officer now owns 145,000 shares in the company, valued at approximately $1,886,450. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CEO Jeffrey N. Simmons bought 100,000 shares of the stock in a transaction on Monday, August 12th. The stock was acquired at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the acquisition, the chief executive officer now owns 145,000 shares of the company’s stock, valued at $1,886,450. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Michael J. Harrington purchased 3,500 shares of the company’s stock in a transaction dated Thursday, August 22nd. The shares were purchased at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the transaction, the director now directly owns 81,094 shares in the company, valued at approximately $1,204,245.90. The disclosure for this purchase can be found here. 0.57% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Elanco Animal Health

Several large investors have recently modified their holdings of ELAN. Mirae Asset Global Investments Co. Ltd. purchased a new position in Elanco Animal Health during the first quarter valued at approximately $1,226,000. Vanguard Group Inc. increased its holdings in shares of Elanco Animal Health by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company’s stock valued at $737,083,000 after acquiring an additional 467,196 shares during the period. Bank of Nova Scotia bought a new position in shares of Elanco Animal Health in the 4th quarter worth $4,004,000. Wolf Hill Capital Management LP purchased a new stake in shares of Elanco Animal Health during the 4th quarter worth $20,683,000. Finally, Jupiter Asset Management Ltd. bought a new stake in Elanco Animal Health during the first quarter valued at about $4,956,000. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.